Why the study?
Does abciximab therapy alter the platelet aggregatory response to PAF and PAF-AH activity in patients with unstable angina?
Population
32 patients with unstable angina and 25 sex- and age-matched healthy controls (n=57 total)
Comparison
Abciximab 0.25 mg/kg bolus followed by a 12-h… vs Untreated unstable angina patients and healthy…
Design
Cohort
Follow-up
1 month
Authors
Loading...
Transient abciximab inhibition in unstable angina may not sustain suppression; hypothesis-generating for adjunctive strategies to address restored reactivity.
Does abciximab therapy alter the platelet aggregatory response to PAF and PAF-AH activity in patients with unstable angina?
Abciximab transiently inhibits the enhanced platelet aggregatory response to PAF in unstable angina, but fails to permanently suppress this heightened reactivity.
Alexandros D. Tselepis (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: